Clinical Trials Logo

Filter by:
NCT ID: NCT01408173 Completed - Clinical trials for Apnea of Prematurity

Clinical Study of Caffeine for Apnea of Prematurity

Start date: August 2011
Phase: Phase 3
Study type: Interventional

The aim of the present Phase III study is to evaluate the safety, efficacy and pharmacokinetics of Caffeine Citrate for treatment of apnea of prematurity in Japan.

NCT ID: NCT01407523 Completed - Epilepsy Clinical Trials

An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures

Start date: July 2011
Phase: Phase 2
Study type: Interventional

To evaluate the safety of Levetiracetam IV 15-minute infusion administered every 12 hours as adjunctive treatment in subjects with Partial Onset Seizures after switching from the equivalent Levetiracetam oral dose.

NCT ID: NCT01407510 Completed - Atopic Dermatitis Clinical Trials

HPA Axis Study in Japanese Adults

Start date: May 9, 2011
Phase: Phase 2
Study type: Interventional

A multicenter, open-label study to evaluate the adrenal suppression potential of Mapracorat 0.1% ointment in Japanese adults with atopic dermatitis.

NCT ID: NCT01407016 Completed - Infection Clinical Trials

A Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Injection In Healthy Japanese Subjects

Start date: August 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of metronidazole following single and multiple intravenous infusion in healthy Japanese adult subjects.

NCT ID: NCT01406938 Completed - Clinical trials for Moderate to Severe Plaque-type Psoriasis

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

SCULPTURE
Start date: August 2011
Phase: Phase 3
Study type: Interventional

This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.

NCT ID: NCT01406574 Completed - Clinical trials for Hepatocellular Carcinoma

Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma

Start date: July 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is: Phase1: To evaluate the safety and determine the recommended dose (RD) Phase2: To evaluate the efficacy

NCT ID: NCT01406249 Active, not recruiting - Gastric Cancer Clinical Trials

XParTS II: Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer

Start date: August 2011
Phase: Phase 2
Study type: Interventional

The aim of this study is to elucidate the efficacy and safety of XP and SP for first-line treatment of Advanced Gastric Cancer.

NCT ID: NCT01404390 Completed - Neoplasms Clinical Trials

Japanese BAY80-6946 Monotherapy Phase I Study

Start date: August 18, 2011
Phase: Phase 1
Study type: Interventional

This study will be conducted as an open label, single centre, Phase I study of PI3K (phosphatidyl inositol 3 kinase) inhibitor BAY80-6946 in Japanese patients with advanced or refractory solid tumours. The eligible subjects will be dosed intravenously at Day 1, Day 8 and Day 15 with three weeks on and one week off in each treatment cycle.

NCT ID: NCT01403818 Completed - Healthy Clinical Trials

A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration

Start date: June 2011
Phase: Phase 1
Study type: Interventional

This study is to assess the pharmacokinetic interaction between ASP1941 and Mitiglinide calcium hydrate in healthy volunteers.

NCT ID: NCT01403805 Completed - Pneumonia Clinical Trials

Effects of the Oral Care With Vaccines for Pneumonia in Elderly; Going Home Together Both Physician and Dentist

Start date: November 2009
Phase: N/A
Study type: Interventional

Prospective study comparing the effects of interventions (combined oral care and pneumococcal plus influenza vaccinations) in preventing pneumonia and increasing the survival rate from pneumonia.